Odyssey Therapeutics Reports 27% Clinical Remission At 20mg In Phase 2a Ulcerative Colitis Trial Of OD-001, Meets Primary Endpoint
Share
Why It Matters
Odyssey Therapeutics tested a new medicine for gut inflammation. Early tests showed it worked on some patients, which is what the team hoped for.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.